An evaluation of the safety of Crodamol PMP.
Crodamol PMP (polyoxypropylene (2) myristyl ether propionate) has been extensively employed for many years in a wide variety of human cosmetics in the absence of reported adverse reactions. The compound is being considered for use as a vehicle for veterinary pharmaceuticals in food-producing animals. This paper reviews information on the chemistry, metabolism, and toxicity of this compound, including the details of a recently completed multi-dose study in rats. Based upon this information, it is concluded that Crodamol PMP is a substance of apparently low toxic potential. Potential new uses of this compound must compare the likely exposure to the substance with the available toxicity information.
SRA International, Inc., Washington, DC, USA.
B K
BK
Bernard
J E
JE
Harris
J E
JE
Fischer
D000818:Animals; D003358:Cosmetics / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005233:Fatty Alcohols / Q000737:chemistry / Q000633:toxicity*; D005260:Female; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D011092:Polyethylene Glycols / Q000737:chemistry / Q000633:toxicity*; D011897:Random Allocation; D051381:Rats; D011919:Rats, Inbred Strains; D019155:Veterinary Drugs / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*
D003358:Cosmetics; D005233:Fatty Alcohols; D019155:Veterinary Drugs; D011092:Polyethylene Glycols; C114849:crodamol PMP